Jeffrey Zapinsky, MD
Urology · Henderson, NVNPI 1366537144
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,535, 2.3 times the $666 reported in 2019.
Across 335 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$821
- Sumitomo Pharma America, Inc.$736
- Antares Pharma, Inc.$709
- Dendreon Pharmaceuticals LLC$532
- Johnson & Johnson$412
- Boston Scientific$355
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,48798%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 35 | $821 |
| Sumitomo Pharma America, Inc. | 36 | $736 |
| Antares Pharma, Inc. | 66 | $709 |
| Dendreon Pharmaceuticals LLC | 24 | $532 |
| Johnson & Johnson | 20 | $412 |
| Boston Scientific | 17 | $355 |
| Urogen Pharma, Inc. | 12 | $331 |
| Endo Pharmaceuticals Inc. | 18 | $267 |
| Telix Pharmaceuticals | 10 | $240 |
| Bayer | 10 | $178 |
| Pfizer | 8 | $165 |
| Medtronic | 1 | $162 |
| Accord Healthcare, Inc. | 8 | $152 |
| 180 Medical, Inc. | 9 | $138 |
| Myriad Genetic Laboratories, Inc. | 6 | $130 |
| Urovant Sciences Inc | 6 | $129 |
| Coloplast | 6 | $122 |
| Melinta Therapeutics, LLC | 1 | $106 |
| AbbVie(2 entities) | 4 | $92 |
| Myovant Sciences Inc. | 4 | $72 |
| Blue Earth Diagnostics | 3 | $71 |
| Endo USA, Inc. | 3 | $64 |
| Merck | 3 | $62 |
| Tolmar Pharmaceuticals, Inc. | 3 | $60 |
| AstraZeneca | 1 | $53 |
| Teleflex LLC | 2 | $47 |
| Axonics, Inc. | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $44 |
| Amgen | 2 | $43 |
| Calyxo, Inc. | 1 | $35 |
| Sanofi | 1 | $29 |
| Novartis | 1 | $23 |
| Immunitybio, Inc. | 1 | $21 |
| Aytu Biopharma, Inc. | 1 | $21 |
| Procept Biorobotics Corporation | 1 | $20 |
| Halozyme Inc | 1 | $20 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $19 |
| ABC Home Medical Supply, Inc. | 1 | $17 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $16 |
| SRS Medical Systems, Inc. | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,587 in reported general payments places this provider in the 55th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 16 | $255,938 |
| GemtesaVibegron | 35 | $27,844 |
| MyrbetriqMirabegron | 30 | $16,870 |
| Tamsulosin Hcl | 915 | $13,554 |
| Finasteride | 596 | $6,396 |
| Testosterone | 25 | $3,014 |
| Testosterone Cypionate | 76 | $2,346 |
| Doxazosin Mesylate | 142 | $2,193 |
| Cephalexin | 173 | $2,051 |
| Potassium Citrate ErPotassium Citrate | 20 | $1,506 |
| NitrofurantoinNitrofurantoin Macrocrystal | 32 | $1,295 |
| Tolterodine Tartrate ErTolterodine Tartrate | 29 | $1,137 |
| Cefdinir | 112 | $1,073 |
| Desmopressin Acetate | 12 | $1,005 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 153 | $815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $821 | $272,80746 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $736 | $27,84435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 63 urology providers in Nevada.
Other urology in Henderson
- Casey McCrawHenderson$23K
- Guillermo PatinoHenderson$15K
- Scott BaranoffHenderson$7K
- Michael FinkelsteinHenderson$3K
- Adam RussonHenderson$2K
- Ralph LarsenHenderson$2K
- William SteinkohlHenderson$1K
- Eliot HorowitzHenderson$125
- Christopher EvansReno$184K
- Vijay GoliLas Vegas$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.